Tiemann Investment Advisors LLC Sells 150 Shares of Abbott Laboratories (NYSE:ABT)

Tiemann Investment Advisors LLC decreased its position in shares of Abbott Laboratories (NYSE:ABT) by 1.5% during the 4th quarter, Holdings Channel reports. The institutional investor owned 9,823 shares of the healthcare product maker’s stock after selling 150 shares during the quarter. Tiemann Investment Advisors LLC’s holdings in Abbott Laboratories were worth $1,111,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently modified their holdings of ABT. Daiwa Securities Group Inc. grew its stake in shares of Abbott Laboratories by 9.1% in the fourth quarter. Daiwa Securities Group Inc. now owns 239,089 shares of the healthcare product maker’s stock valued at $27,043,000 after acquiring an additional 19,860 shares in the last quarter. Main Street Research LLC grew its position in shares of Abbott Laboratories by 12.3% during the 4th quarter. Main Street Research LLC now owns 3,857 shares of the healthcare product maker’s stock worth $436,000 after purchasing an additional 421 shares in the last quarter. Isthmus Partners LLC bought a new position in shares of Abbott Laboratories during the fourth quarter worth approximately $552,000. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Abbott Laboratories by 3.2% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 732,945 shares of the healthcare product maker’s stock valued at $82,903,000 after buying an additional 22,705 shares in the last quarter. Finally, Sound View Wealth Advisors Group LLC boosted its stake in shares of Abbott Laboratories by 3.8% in the fourth quarter. Sound View Wealth Advisors Group LLC now owns 28,289 shares of the healthcare product maker’s stock valued at $3,200,000 after buying an additional 1,046 shares during the period. Institutional investors and hedge funds own 75.18% of the company’s stock.

Insider Buying and Selling at Abbott Laboratories

In other news, SVP Eric Shroff sold 562 shares of the firm’s stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $138.17, for a total transaction of $77,651.54. Following the completion of the sale, the senior vice president now owns 31,970 shares of the company’s stock, valued at $4,417,294.90. This trade represents a 1.73 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, EVP Lisa D. Earnhardt sold 91,167 shares of the business’s stock in a transaction on Thursday, March 6th. The shares were sold at an average price of $133.82, for a total transaction of $12,199,967.94. Following the transaction, the executive vice president now owns 71,928 shares in the company, valued at $9,625,404.96. The trade was a 55.90 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 116,449 shares of company stock valued at $15,463,316. 1.10% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of brokerages recently commented on ABT. Evercore ISI raised their price target on Abbott Laboratories to $136.00 and gave the stock a “buy” rating in a research report on Thursday, January 2nd. Royal Bank of Canada reissued an “outperform” rating and issued a $135.00 target price on shares of Abbott Laboratories in a report on Tuesday, January 21st. Barclays reaffirmed an “overweight” rating and set a $158.00 price target (up previously from $149.00) on shares of Abbott Laboratories in a report on Monday, January 27th. Wells Fargo & Company boosted their price objective on shares of Abbott Laboratories from $133.00 to $136.00 and gave the company an “overweight” rating in a research report on Thursday, January 23rd. Finally, Citigroup raised their target price on Abbott Laboratories from $135.00 to $160.00 and gave the company a “buy” rating in a report on Tuesday, March 4th. Four investment analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $137.19.

Abbott Laboratories Stock Up 1.6 %

Shares of NYSE ABT opened at $137.23 on Monday. The company has a 50 day simple moving average of $125.35 and a 200 day simple moving average of $118.82. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.60 and a quick ratio of 1.14. Abbott Laboratories has a 1 year low of $99.71 and a 1 year high of $141.23. The firm has a market cap of $238.00 billion, a PE ratio of 17.94, a price-to-earnings-growth ratio of 2.52 and a beta of 0.70.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings results on Wednesday, January 22nd. The healthcare product maker reported $1.34 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.34. Abbott Laboratories had a net margin of 31.95% and a return on equity of 20.74%. The firm had revenue of $10.97 billion during the quarter, compared to the consensus estimate of $11.03 billion. During the same quarter last year, the firm earned $1.19 earnings per share. The company’s revenue for the quarter was up 7.2% on a year-over-year basis. On average, research analysts forecast that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, May 15th. Stockholders of record on Tuesday, April 15th will be given a dividend of $0.59 per share. The ex-dividend date of this dividend is Tuesday, April 15th. This represents a $2.36 dividend on an annualized basis and a dividend yield of 1.72%. Abbott Laboratories’s dividend payout ratio (DPR) is 30.85%.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.